In continuation to its earlier intimation dated October 23, 2024, Jagsonpal Pharmaceuticals has informed that it enclosed a copy of revised Investor Presentation for the Unaudited Financial results for the quarter and half year ended September 30, 2024, due to an inadvertent error in slide 20 which has been rectified.
The above information is a part of company’s filings submitted to BSE.